Announced details
The Company plans to occupy DP-Lab KOBE. DAIWA HOUSE INDUSTRY CO.,LTD. is the construction company for the rental laboratory. Capital and personnel relationships are Not disclosed.
The company that built DP-Lab KOBE within the Kobe Biomedical Innovation Cluster (KBIC). Other information, including its location, representative, capital and year of establishment, is Not disclosed.
6-3-10 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo Prefecture (DP-Lab KOBE)
There will be no impact on consolidated earnings for the fiscal year ending December 2026. The Company will promptly disclose any matters requiring disclosure that arise in the future.
The company does not address Contract Value / Offering price.
Ministry of Economy, Trade and Industry, FY2024 supplementary budget, "Subsidy Program for Supporting Capital Investment in Manufacturing Facilities for Regenerative Medicine, Cell Therapy and Gene Therapy"
| Item | Details |
|---|---|
| Names of Products / Services Covered | Healios / KOBE Cell Innovation Center（KCIC）, CDMO (contract development and manufacturing) business |
| Counterparty | DAIWA HOUSE INDUSTRY CO.,LTD. |
| Counterparty overview | The company that built DP-Lab KOBE within the Kobe Biomedical Innovation Cluster (KBIC). Other information, including its location, representative, capital and year of establishment, is Not disclosed. |
| Relationship with the Company | The Company plans to occupy DP-Lab KOBE. DAIWA HOUSE INDUSTRY CO.,LTD. is the construction company for the rental laboratory. Capital and personnel relationships are Not disclosed. |
| Launch date | Scheduled to begin operations in January 2028 |
| Applicable area | Regenerative Medicine, Cell therapy, Contract development and manufacturing (CDMO), Biotechnology and life sciences |
| Location | 6-3-10 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo Prefecture (DP-Lab KOBE) |
| Location scale | DP-Lab KOBE: total floor area of 9,144.42 m², with 6 above-ground floors and 1 penthouse floor. KCIC: floors 4 through 6, 1,040 m² per floor. |
| Impact on Business Performance | There will be no impact on consolidated earnings for the fiscal year ending December 2026. The Company will promptly disclose any matters requiring disclosure that arise in the future. |
| Source | Ministry of Economy, Trade and Industry, FY2024 supplementary budget, "Subsidy Program for Supporting Capital Investment in Manufacturing Facilities for Regenerative Medicine, Cell Therapy and Gene Therapy" |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To establish a cell manufacturing facility capable of serving global markets, build a supply system for cell products using three-dimensional culture, and fully launch the CDMO business.